These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26080606)

  • 1. Current State of Immunosuppression: Past, Present, and Future.
    Karam S; Wali RK
    Crit Rev Eukaryot Gene Expr; 2015; 25(2):113-34. PubMed ID: 26080606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
    Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD008852. PubMed ID: 22419339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.
    Wong TC; Lo CM; Fung JY
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression for lung transplantation: evidence to date.
    Snell GI; Westall GP
    Drugs; 2007; 67(11):1531-9. PubMed ID: 17661526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression.
    Söderlund C; Rådegran G
    Transplant Rev (Orlando); 2015 Jul; 29(3):181-9. PubMed ID: 25812489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants.
    Mueller XM
    Ann Thorac Surg; 2004 Jan; 77(1):354-62. PubMed ID: 14726104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the prophylaxis and treatment of graft versus host disease.
    Simpson D
    Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression and Heart Transplantation.
    Sutaria N; Sylvia L; DeNofrio D
    Handb Exp Pharmacol; 2022; 272():117-137. PubMed ID: 34671867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.